Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 12/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600019 | 0.94 | SMYD2 (0.57) | SMYD2ADRB2DRD2DRD1DRD4 | |
| SCHEMBL3601636 | 0.94 | SMYD2 (0.66) | SMYD2ADRB2DRD2DRD1DRD4 | |
| SCHEMBL3591045 | 0.94 | SMYD2 (0.66) | SMYD2ADRB2DRD2DRD1DRD4 | |
| SCHEMBL3596829 | 0.93 | SMYD2 (0.65) | SMYD2ADRB2DRD2DRD1DRD4 | |
| SCHEMBL3600112 | 0.93 | SMYD2 (0.56) | SMYD2ADRB2DRD2DRD1DRD4 | |
| SCHEMBL3600077 | 0.92 | SMYD2 (0.56) | SMYD2ADRB2DRD2DRD1DRD4 | |
| SCHEMBL3594023 | 0.92 | SMYD2 (0.53) | SMYD2ADRB2DRD2DRD1DRD4 | |
| SCHEMBL3597613 | 0.90 | SMYD2 (0.57) | SMYD2ADRB2DRD2DRD1DRD4 | |
| SCHEMBL3593899 | 0.89 | SMYD2 (0.56) | SMYD2ADRB2DRD2DRD1DRD4 | |
| SCHEMBL3602036 | 0.89 | SMYD2 (0.54) | SMYD2ADRB2DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| EP-2094646-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008075025-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | AR, ADRA1D, ADRA1B | SMYD2 3203/4885ADRB2 18/4885DRD2 23/4885 |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ADRB2, ADRB1, ADRA2A | SMYD2 1024/4885ADRB2 1/4885DRD2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.